DUBLIN--(BUSINESS WIRE)--GE Healthcare today presented the results of a randomised controlled study analyzing the effect of DaTSCAN™ (Ioflupane I 123 Injection) SPECT imaging in a group of adult ...

Parkinson’s disease (PD), the second-most common neurodegenerative disease, is characterized by motor and nonmotor symptoms. PD is often misdiagnosed; inappropriate treatment due to misdiagnosis has ...

DaTscan is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult ...

First patient dosed in Phase III clinical trial for PET radiopharmaceutical Next stage clinical study also proceeding for SPECT radiopharmaceutical Both imaging agents aim to assist in the evaluation ...

January 17, 2011 — GE Healthcare has announced Food and Drug Administration (FDA) approval of ioflupane iodine-123 injection (DaTscan), a contrast agent for use with single-photon emission computed ...

Thanks to a new diagnostic imaging technique, physicians now have an objective test to evaluate patients for parkinsonian syndromes, such as Parkinson's disease. Northwestern Memorial Hospital is ...

DaTscan is a radioactive diagnostic agent that works by binding reversibly to the human dopamine transporter (DaT) in the brain. The Food and Drug Administration (FDA) has expanded the approval of ...

The imaging agent, ioflupane I 123 (DaTscan; GE Healthcare), has been removed from the schedules of the US Controlled Substances Act, meaning that it will be more widely available for use in the ...

CHICAGO –Thanks to a new diagnostic imaging technique, physicians now have an objective test to evaluate patients for parkinsonian syndromes, such as Parkinson's disease. Northwestern Memorial ...

DaTscan (ioflupane I 123 injection; GE Healthcare) was found to improve a physician’s ability to definitively diagnose patients with dementia with Lewy bodies (DLB) and increase their confidence in ...

The Parkinson’s Progression Markers Initiative (PPMI) was launched in July with hopes of identifying a biomarker, or set of markers, that tracks the natural course of Parkinson disease in 400 newly ...

This supplement to The American Journal of Managed Care summarizes proceedings from a roundtable meeting that was conducted to discuss the diagnosis of Parkinson’s disease and distinguish clinical ...